1. Articles in category: Tumor Biology

    1-24 of 41 1 2 »
    1. Investigational drugs in phase II clinical trials for the treatment of neuroblastoma.

      Investigational drugs in phase II clinical trials for the treatment of neuroblastoma.

      Expert Opin Investig Drugs. 2017 Sep 14;:

      Authors: Amoroso L, Haupt R, Garaventa A, Ponzoni M

      Abstract INTRODUCTION: Neuroblastoma (NB) is an embryonal tumor originating from undifferentiated neural crest cell, highly heterogeneous ranging from spontaneous regression to progression despite multimodal treatments.

      Read Full Article
      Mentions: Treatment
    2. High-risk neuroblastoma in a sub-Saharan African country: telling it like it is.

      High-risk neuroblastoma in a sub-Saharan African country: telling it like it is.

      Trop Doct. 2017 Jan 01;:49475517704363

      Authors: Hadley GP, van Heerden J

      Abstract Neuroblastoma is uncommon in Africa, but when seen usually presents as high-risk disease with a poor prognosis. This aggressive biology of the tumour is frequently augmented by delayed presentation.

      Read Full Article
    3. Significance of tumor biology compared to metastatic pattern (INSS 4 versus 4s) and age for prognosis of neuroblastoma less than 18 months of age.

      "For patients with MYCN not amplified tumors, outcome for patients 12-18 months is similar to those <12 months regardless of the pattern of metastases. Tumor biology is more critical than metastatic pattern for prognosis of patients aged 12-18 months with stage 4 neuroblastoma."

      Read Full Article
      Mentions: MYCN LDH
    4. Neuroblastoma: A Tough Nut to Crack.

      "These advances have resulted in a growing population of long-term survivors of neuroblastoma. Examination of the late effects and second malignant neoplasms (SMNs) in both older generations of survivors and more recently treated survivors will inform both design of future trials and surveillance guidelines for long-term follow-up. As a consequence of advances in understanding of the biology of neuroblastoma, successful clinical trials, and refined understanding of the late effects and SMNs of survivors, the promise of precision medicine is becoming a reality for patients with neuroblastoma."

      Read Full Article
      Mentions: Treatment MYCN
    5. Low Frequency of Programmed Death Ligand 1 Expression in Pediatric Cancers

      Programmed death 1 (PD-1)/programmed death ligand 1 (PD-L1) pathway blockade has become a promising therapeutic target in adult cancers. We evaluated PD-L1 expression and tumor-infiltrating CD8+ T cells in formalin-fixed, paraffin-embedded tumor specimens from 53 untreated pediatric patients with eight cancer types: neuroblastoma, extracranial malignant germ cell tumor, hepatoblastoma, germinoma, medulloblastoma, renal tumor, rhabdomyosarcoma, and atypical teratoid/rhabdoid tumor.

      Read Full Article
      Mentions: PD-1
    6. Cyclin D1 in human neuroblastic tumors recapitulates its developmental expression: An immunohistochemical study.

      Cyclin D1 in human neuroblastic tumors recapitulates its developmental expression: An immunohistochemical study.

      Acta Histochem. 2015 May-Jun;117(4-5):415-24

      Authors: Magro G, Salvatorelli L, Di Cataldo A, Musumeci G, Spoto G, Parenti R

      Abstract The protein cyclin D1 (CD1), which belongs to a family of proteins functioning as regulators of CDKs (cyclin-dependent kinases) throughout the cell cycle, has been immunohistochemically detected in a wide variety of human malignant tumors.

      Read Full Article
    7. Using New Drug Screening Tool, UNC Researchers Identify Potential Treatments for Ewing Sarcoma

      In a first-of-its-kind-study, researchers at the University of North Carolina Lineberger Comprehensive Cancer Center discovered and applied a new screening technique capable of testing thousands of potential drug compounds to see if those compounds can reverse abnormal DNA unwinding in Ewing sarcoma, a bone and soft tissue cancer that's most common in teens and young adults.

      Read Full Article
      Mentions: Genetics
    8. The mitochondrial genetic landscape in neuroblastoma from tumor initiation to relapse.

      The mitochondrial genetic landscape in neuroblastoma from tumor initiation to relapse.

      Oncotarget. 2015 Dec 28;

      Authors: Riehl LM, Schulte JH, Mulaw MA, Dahlhaus M, Fischer M, Schramm A, Eggert A, Debatin KM, Beltinger C

      Abstract Little is known about changes within the mitochondrial (mt) genome during tumor progression in general and during initiation and progression of neuroblastoma (NB) in particular.

      Read Full Article
    9. Change in a Single DNA Base Drives a Childhood Cancer -- Chop Researchers Detail how a Super-Enhancer Gene Causes High-Risk Neuroblastoma --

      Change in a Single DNA Base Drives a Childhood Cancer -- Chop Researchers Detail how a Super-Enhancer Gene Causes High-Risk Neuroblastoma --

      PHILADELPHIA, Nov. 11, 2015 /PRNewswire-USNewswire/ -- Pediatric oncology researchers have pinpointed a crucial change in a single DNA base that both predisposes children to an aggressive form of the childhood cancer neuroblastoma and makes the disease progress once tumors form. The change in the LMO1 gene results in a "super-enhancer," driving abnormally increased biological activity in the gene, resulting in tumor formation and progression.

      Read Full Article
    10. Influence of hypoxia-dependent factors on the progression of neuroblastoma.

      Influence of hypoxia-dependent factors on the progression of neuroblastoma.

      Pediatr Surg Int. 2015 Oct 28;

      Authors: Ameis HM, Drenckhan A, Freytag M, Izbicki JR, Supuran CT, Reinshagen K, Holland-Cunz S, Gros SJ

      Abstract PURPOSE: Several oxygen-dependent factors, e.g., CAIX (carbonic anhydrase IX) or phosphoglycerate kinase 1 (PGK1) interacting with the CXCR4/SDF1 axis (chemokine receptor 4/stromal cell derived factor 1) have been shown to be involved in processes of tumour pathology including tumourigenicity, tumour cell dissemination and poor survival in several solid tumour entities. The aim of the current study was to evaluate the influence of the hypoxia-inducible ...

      Read Full Article
    11. Identification of GALNT14 as a novel neuroblastoma predisposition gene.

      Identification of GALNT14 as a novel neuroblastoma predisposition gene.

      Oncotarget. 2015 Jul 3;

      Authors: De Mariano M, Gallesio R, Chierici M, Furlanello C, Conte M, Garaventa A, Croce M, Ferrini S, Tonini GP, Longo L

      Abstract Although several genes have been associated to neuroblastoma (NB) predisposition and aggressiveness, further genes are likely involved in the overall risk of developing this pediatric cancer.

      Read Full Article
      Mentions: ALK MYCN
    12. Expression of MYCN in Multipotent Sympathoadrenal Progenitors Induces Proliferation and Neural Differentiation, but Is Not Sufficient for Tumorigenesis.

      "We isolated sympathoadrenal progenitor cells from the postnatal murine adrenal gland by sphere culture and found them to be multipotent, generating differentiated colonies of neurons, Schwann cells, and myofibroblasts. MYCN overexpression in spheres promoted commitment to the neural lineage, evidenced by an increased frequency of neuron-containing colonies. MYCN promoted proliferation of both sympathoadrenal progenitor spheres and differentiated neurons derived from these spheres, but there was also an increase in apoptosis. The proliferation, apoptosis, and neural lineage commitment induced by MYCN are tumor-like characteristics and thereby support the hypothesis that multipotent adrenal medullary progenitor cells are cells of origin for neuroblastoma ...

      Read Full Article
      Mentions: Surgery MYCN
    13. MicroRNA-203 inhibits the malignant progression of neuroblastoma by targeting Sam68.

      Neuroblastoma (NB) is the most common solid extracranial tumor in children. However, the molecular mechanism of NB remains to be elucidated. In the present study, reverse transcription quantitative polymerase chain reaction data demonstrated that the expression of Sam68 was significantly upregulated in NB tissues compared with their matched adjacent normal tissues.

      Read Full Article
    14. Phox2B correlates with MYCN and is a prognostic marker for neuroblastoma development.

      AbstractNeuroblastoma is the one of the most common extracranial childhood malignancies, accounting for ∼15% of tumor-associated deaths in children. It is generally considered that neuroblastoma originates from neural crest cells in the paravertebral sympathetic ganglia and the adrenal medulla. However, the mechanism by which neuroblastoma arises during sympathetic neurogenesis and the cellular mechanism that drives neuroblastoma development remains unclear.

      Read Full Article
      Mentions: MYCN PHOX2B
    15. Tackling Crizotinib Resistance: The Pathway from Drug Discovery to the Pediatric Clinic.

      1Paediatric Solid Tumour Biology and Therapeutics Team, Division of Cancer Therapeutics, The Institute of Cancer Research, London, United Kingdom. 2Cancer Research UK Cancer Therapeutics Unit, Division of Cancer Therapeutics, The Institute of Cancer Research, London, United Kingdom. 3Paediatric Solid Tumour Biology and Therapeutics Team, Division of Cancer Therapeutics, The Institute of Cancer Research, London, United Kingdom. Louis.Chesler@icr.ac.uk.

      Read Full Article
      Mentions: ALK
    16. Mutational dynamics between primary and relapse neuroblastomas.

      Neuroblastoma is a malignancy of the developing sympathetic nervous system that is often lethal when relapse occurs. We here used whole-exome sequencing, mRNA expression profiling, array CGH and DNA methylation analysis to characterize 16 paired samples at diagnosis and relapse from individuals with neuroblastoma.

      Read Full Article
      Mentions: Relapse
    17. mPGES-1 in neuroblastoma [Medical Sciences]

      Cancer-related inflammation promotes progression and therapy resistance in tumors of adulthood. Knowledge concerning the significance of inflammation in childhood malignancies has been limited. Neuroblastoma is an embryonal tumor of early childhood with poor prognosis despite intensified therapy, and biological understanding is necessary to develop novel therapies.

      Read Full Article
    18. Pinpointing Mutations in a Relapsed Cancer May Lead to Better Treatments

      Researchers studying the pediatric cancer neuroblastoma have detailed how cancer-driving mutations evolve during chemotherapy, and they hope to exploit this knowledge to design better treatments for children.

      “Our greater understanding of mutations on a crucial biological pathway offers prospects of acting on these pathways for direct benefit to children with this aggressive form of neuroblastoma,” said senior author John M. Maris, MD, a pediatric oncologistat The Children’s Hospital of Philadelphia.

      Read Full Article
    19. Moffitt Develops New Method to Characterize the Structure of a Protein That Promotes Tumor Growth

      "Moffitt scientists study the structure of MDMX to understand how it blocks p53 activity and to use this information in the development of cancer therapeutic drugs. However, many techniques commonly used to study protein structures have different drawbacks, limiting their usefulness on MDMX.  The researchers developed a novel technique called the proteolytic fragment release assay to analyze the MDMX protein. This assay allows scientists to determine how different segments of a protein interact with one another."

      Read Full Article
    1-24 of 41 1 2 »
  1. Categories

    1. Research:

      Cancer Cell, Case Report, Cells and Stem Cells, Clinical Research, Conferences, Disease Classification, Drug, Drug Delivery, Drug Resistance, Epigenetics and Epigenomics, General, Genetics, Genomics, Guidelines, Immune Therapy, Induction, Long Term Effects, Low / Intermediate Risk, Nanotechnology, Olfactory Neuroblastoma, Onco-Fertility, Oncogenesis, Other Cancers, Personalized Medicine, Pharma, Pre-Clinical, Prognostics, PubMed, Review, Small Molecules, Surgery, Survivorship, Trials, Tumor Biology, Virotherapy
    2. Business:

      Funding, IP, Pharma
    3. Non-Profit:

      Advocacy, Charity, Events, Foundation, Funding, Human Interest
    4. Press Release:

      Announcement, News, Pharma
    5. General:

      Adolescent and Young Adults, Bioethics, Blog, Burden of Treatment, Children & Families, Diagnosis and Detection, Drug Development, Epidemiology, Imaging, Incidence, Information, News, Overview of the Disease, Pain Control, Palliative Care, Psychosocial, Regulation, Side-Effects, Social, Supportive Care, Treatment
    6. Media:

      Audio, Blogs, Video
  2. Popular Articles

  3. General Informations in the News

    1. (1 articles) Treatment